UNSPSC 51172115: Amikhelline

This classification denotes an antispasmotic agent with the molecular formula C18H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BD9T227F6M, chemically known as 9(2-(diethylamino)ethoxy)-4-hydroxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one but generally known as amikhelline, which bears US NIH Compound Identifier 71198. European Medicines Agency schedules Amikhelline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05432MIG.

UNSPSC 51172115 Amikhelline is a Commodity code for a pharmaceutical product that shows limited relevance to current state and local procurement activity. The recent opportunities posted under this code do not reflect procurement of amikhelline itself; instead, they address broader pharmaceutical supply and drug testing services. Collin County Community Supervision and Corrections Department solicited offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026) encompassing immunoassay screening, LC/MS/MS and GC/MS confirmation, and alternative testing methodologies for approximately 25,031 annual tests under an estimated $600,000 contract. The Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs (RFI HHS0017013, April 3, 2026) to explore alternative pharmacy benefit models outside traditional PBM arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and OTC products (RFP S1070000015802, due March 26, 2026) requiring manufacturers to supply products through three authorized wholesalers with comprehensive pricing and NDC documentation. The issuing bodies represent county corrections departments, state health commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions.

The code's recent activity spans Texas and Minnesota, with MMCAP's cooperative procurement extending to participating state and local facilities in Oregon. The opportunities reflect broader pharmaceutical procurement and testing infrastructure rather than procurement of amikhelline as a discrete product line. Collin County's RFP emphasized per-test pricing models with annual price redetermination capped at 3.0 percent, lab certification requirements from SAMHSA or state regulatory bodies, and a two-year term with optional three one-year renewals. MMCAP's RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three authorized wholesalers, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and carry $5,000,000 commercial general liability insurance. No recent solicitations specifically name amikhelline as a procured item, suggesting the code may be incorrectly tagged in state and local notices or reflects minimal direct demand for this product under its nominal UNSPSC classification.